title: [Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis].
abstract: Evidence of the analgesic effects of nonsteroidal antiinflammatory drugs in human diseases is easy to collect. However, demonstration of differences in the activity of NSAIDs according to the route of administration is considerably more difficult. Forty patients with rheumatoid arthritis were given either one intramuscular injection of 100 mg ketoprofen with two placebo capsules or one intramuscular injection of placebo with two 50 mg ketoprofen capsules. Analysis of changes in pain severity over the six-hour study period failed to disclose any statistically significant differences between the two groups. However, time to peak effectiveness (Tmax) was significantly shorter with the intramuscular route (194 +/- 118 minutes) than with the oral route (276 +/- 111 minutes) (p = 0.029). Although intramuscular NSAID therapy is rarely warranted in RA patients, these findings suggest that RA may serve as a clinical model for evaluating the effectiveness of a NSAID according to the route of administration.
authors.affiliation: Clinique de Rhumatologie, Hôpital Cochin, Paris.
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: V
authors.initials: V
authors.lastname: Listrat
authors.forename: L
authors.initials: L
authors.lastname: Duchesne
authors.forename: B
authors.initials: B
authors.lastname: Amor
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007273:Injections, Intramuscular; D007660:Ketoprofen / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D007660:Ketoprofen
vernacular_title: Efficacité comparée du kétoprofène en fonction de sa voie d'administration (intra-musculaire ou per os). Une étude en double aveugle contre placebo au cours de la polyarthrite rhumatoïde.